Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 6:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 83,877 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: therapy Clear all
Completed Phase 2 Interventional

Effectiveness of the Early Addition of Abacavir to an Anti-HIV Drug Combination

NCT00001132
View directory record Official record
Conditions
HIV Infections
Interventions
Abacavir sulfate
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
29
States / cities
Los Angeles, California • Menlo Park, California • San Jose, California + 19 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2008 · Synced Oct 27, 2026, 6:03 AM EDT
Suspended Early Phase 1 Interventional

PBA Use for Treatment of ATF6-/- Patients

NCT04041232
View directory record Official record
Conditions
ACHROMATOPSIA 7, Achromatopsia
Interventions
PBA
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 27, 2026, 6:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Roo Study on Mom and Baby Well-Being

NCT03809598
View directory record Official record
Conditions
Maternal Psychological Distress, Prenatal Stress, Infant Development, Functional Neuroimaging, Pregnancy Related
Interventions
Mindfulness Based Cognitive Therapy
Behavioral
Lead sponsor
Oregon Health and Science University
Other
Eligibility
3 Days to 45 Years · Female only
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 29, 2023 · Synced Oct 27, 2026, 6:03 AM EDT
Completed Not applicable Interventional

Coherence Training for Military Personnel

NCT01599598
View directory record Official record
Conditions
Stress
Interventions
Progressive Muscle Relaxation, Coherence Advantage
Behavioral
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
Not listed
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2016 · Synced Oct 27, 2026, 6:03 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer

NCT02562898
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
Ibrutinib, Paclitaxel, Gemcitabine
Drug
Lead sponsor
Margaret Tempero
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
San Francisco, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Oct 27, 2026, 6:03 AM EDT
Completed Phase 2 Interventional Results available

Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia

NCT00528398
View directory record Official record
Conditions
Leukemia
Interventions
cytarabine, idarubicin
Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
16 Years to 60 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2015
U.S. locations
2
States / cities
Phoenix, Arizona • Duarte, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Oct 27, 2026, 6:03 AM EDT
Terminated Not applicable Interventional Results available

Cysteamine Therapy for Major Depressive Disorder

NCT00715559
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
cysteamine bitartrate
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2017 · Synced Oct 27, 2026, 6:03 AM EDT
Completed Not applicable Interventional Results available

A Tailored, Peer-delivered Intervention to Reduce Recurring Opioid Overdoses

NCT02922959
View directory record Official record
Conditions
Drug Overdose, Opioid-Related Disorders, Drug Addiction, Drug Abuse, Substance Abuse
Interventions
Peer Intervention, naloxone nasal spray kit, Personally-tailored opioid overdose prevention education (information packet)
Behavioral · Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 24, 2020 · Synced Oct 27, 2026, 6:03 AM EDT
Completed Phase 2 Interventional

Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus

NCT02015559
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Oral Complications, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
mucoadhesive oral wound rinse, laboratory biomarker analysis
Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Oct 27, 2026, 6:03 AM EDT
Completed Phase 2 Interventional Results available

Dupilumab for the Treatment of Moderate to Severe Chronic Hepatic Pruritus

NCT04256759
View directory record Official record
Conditions
Pruritus
Interventions
Dupilumab 300Mg Solution for Injection
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 27, 2026, 6:03 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of the Effect of Low Level Laser Light Therapy on Reducing the Appearance of Cellulite in the Thighs and Buttocks.

NCT01702259
View directory record Official record
Conditions
Cellulite
Interventions
Erchonia Scanner device (GLS), Placebo device
Device
Lead sponsor
Erchonia Corporation
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
2
States / cities
Marion, Indiana • Bloomfield Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 11, 2015 · Synced Oct 27, 2026, 6:03 AM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate the Safety of BF-200 ALA (Ameluz®) for Photodynamic Therapy (PDT) in the Treatment of Expanded Fields of Actinic Keratosis (AK)

NCT04319159
View directory record Official record
Conditions
Actinic Keratoses
Interventions
BF-200 ALA and red light LED lamp
Combination Product
Lead sponsor
Biofrontera Bioscience GmbH
Industry
Eligibility
18 Years to 85 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Oct 27, 2026, 6:03 AM EDT
Terminated Phase 3 Interventional Results available

Stroke With Transfusions Changing to Hydroxyurea

NCT00122980
View directory record Official record
Conditions
Hemochromatosis, Cerebrovascular Accident, Anemia, Sickle Cell, Hematologic Diseases
Interventions
Red Cell Transfusions, Iron Chelation, Hydroxyurea, Phlebotomy
Procedure · Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
5 Years to 18 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
28
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • Jacksonville, Florida + 23 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 27, 2026, 6:03 AM EDT
Not yet recruiting Phase 2 Interventional

Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer

NCT07593079
View directory record Official record
Conditions
Prostate Cancer, Recurrent Prostate Cancer, Metastatic Prostate Cancer, Prostate Cancer Recurrent, Prostate Cancer Metastatic
Interventions
Bicalutamide, Prostate-specific membrane antigen Positron Emission Tomography-Computed Tomography, 18F-rhPSMA-7.3, PROSTest
Drug · Device · Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 27, 2026, 6:03 AM EDT
Recruiting Not applicable Interventional

Preventing the Development of Chronic Pain: Treating PTSD at Acute Pain Onset

NCT05700279
View directory record Official record
Conditions
PTSD, Chronic Pain
Interventions
Stellate Ganglion Block, Cognitive Processing Therapy
Procedure · Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 27, 2026, 6:03 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Mindfulness Meditation in Older Adults

NCT01532596
View directory record Official record
Conditions
Aging
Interventions
Mindfulness-Based Stress Reduction
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
55 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2012 · Synced Oct 27, 2026, 6:03 AM EDT
Completed Not applicable Interventional Results available

Transcranial Direct Stimulation (tDCS) and Behavioral Intervention in Aphasia

NCT02226796
View directory record Official record
Conditions
Aphasia
Interventions
Transcranial direct current stimulation
Device
Lead sponsor
University of Minnesota
Other
Eligibility
20 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 18, 2022 · Synced Oct 27, 2026, 6:03 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD

NCT04201262
View directory record Official record
Conditions
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
Interventions
Ravulizumab
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
10
States / cities
Aurora, Colorado • Fort Collins, Colorado • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 27, 2026, 6:03 AM EDT
Terminated Not applicable Interventional

Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of Response to Therapy in Metastatic Renal Cell Carcinoma

NCT00953446
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Oct 27, 2026, 6:03 AM EDT
Completed Not applicable Interventional

Integrated Intervention Post-Sexual Assault

NCT04724746
View directory record Official record
Conditions
Substance Use Disorders, Posttraumatic Stress Disorder, Sexual Assault
Interventions
Written Exposure and Cognitive Behavioral Therapy
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Oct 27, 2026, 6:03 AM EDT
Active, not recruiting Phase 2 Interventional

Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients

NCT07116746
View directory record Official record
Conditions
Gout, Gouty Arthritis, Hyperuricemia, Gout Chronic, Refractory Gout, Uncontrolled Gout, Tophaceous Gout
Interventions
AR882 75 mg, XOI Low Dose, XOI High Dose
Drug
Lead sponsor
Arthrosi Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
Margate, Florida • Miami, Florida • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 27, 2026, 6:03 AM EDT
Terminated Not applicable Interventional Results available

FDG-PET in Advanced Melanoma

NCT02236546
View directory record Official record
Conditions
Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
Interventions
[18F]fluorodeoxyglucose, Molecular assays on biopsied tissue, positron emission tomography, computed tomography
Diagnostic Test · Other · Device
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 27, 2026, 6:03 AM EDT
Recruiting Phase 2 Interventional

EMERALD: Endocrine Therapy oMission With Radiation in ER+ Breast Cancer: Assessing Quality of Life and Disease Control: a Prospective Phase II Trial

NCT06897488
View directory record Official record
Conditions
Breast Cancer
Interventions
Adjuvant Radiotherapy
Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
60 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 27, 2026, 6:03 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.

NCT02032888
View directory record Official record
Conditions
Hepatitis C
Interventions
Daclatasvir, Sofosbuvir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
37
States / cities
Birmingham, Alabama • Beverly Hills, California • Long Beach, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Oct 27, 2026, 6:03 AM EDT